The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience

På svenska

Author

  • Joachim Burman
  • Ellen Iacobaeus
  • Anders Svenningsson
  • Jan Lycke
  • Martin Gunnarsson
  • Petra Nilsson
  • Magnus Vrethem
  • Sten Fredrikson
  • Claes Martin
  • Anna Sandstedt
  • Bertil Uggla
  • Stig Lenhoff
  • Jan-Erik Johansson
  • Cecilia Isaksson
  • Hans Hagglund
  • Kristina Carlson
  • Jan Fagius
Show all

Summary, in English

Background Autologous haematopoietic stem cell transplantation (HSCT) is a viable option for treatment of aggressive multiple sclerosis (MS). No randomised controlled trial has been performed, and thus, experiences from systematic and sustained follow-up of treated patients constitute important information about safety and efficacy. In this observational study, we describe the characteristics and outcome of the Swedish patients treated with HSCT for MS. Methods Neurologists from the major hospitals in Sweden filled out a follow-up form with prospectively collected data. Fifty-two patients were identified in total; 48 were included in the study and evaluated for safety and side effects; 41 patients had at least 1 year of follow-up and were further analysed for clinical and radiological outcome. In this cohort, 34 patients (83%) had relapsing-remitting MS, and mean follow-up time was 47 months. Results At 5 years, relapse-free survival was 87%; MRI event-free survival 85%; expanded disability status scale (EDSS) score progression-free survival 77%; and disease-free survival (no relapses, no new MRI lesions and no EDSS progression) 68%. Presence of gadolinium-enhancing lesions prior to HSCT was associated with a favourable outcome (disease-free survival 79% vs 46%, p=0.028). There was no mortality. The most common long-term side effects were herpes zoster reactivation (15%) and thyroid disease (8.4%). Conclusions HSCT is a very effective treatment of inflammatory active MS and can be performed with a high degree of safety at experienced centres.

Publishing year

2014

Language

English

Pages

1116-1121

Publication/Series

Journal of Neurology, Neurosurgery and Psychiatry

Volume

85

Issue

10

Document type

Journal article

Publisher

BMJ Publishing Group

Topic

  • Neurology

Status

Published

ISBN/ISSN/Other

  • ISSN: 1468-330X